Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials

The phase 2b AMP trials are testing whether the broadly neutralising antibody VRC01 prevents HIV-1 infection in two cohorts: women in sub-Saharan Africa, and men and transgender persons who have sex with men (MSM/TG) in the Americas and Switzerland. We used nonlinear mixed effects modelling of longi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:EBioMedicine
Asıl Yazarlar: Huang, Yunda, Naidoo, Logashvari, Zhang, Lily, Carpp, Lindsay N., Rudnicki, Erika, Randhawa, April, Gonzales, Pedro, McDermott, Adrian, Ledgerwood, Julie, Lorenzo, Margarita M.Gomez, Burns, David, DeCamp, Allan, Juraska, Michal, Mascola, John, Edupuganti, Srilatha, Mgodi, Nyaradzo, Cohen, Myron, Corey, Lawrence, Andrew, Philip, Karuna, Shelly, Gilbert, Peter B., Mngadi, Kathryn, Lazarus, Erica
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Elsevier 2021
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7841500/
https://ncbi.nlm.nih.gov/pubmed/33493795
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2020.103203
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller